These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11367188)

  • 41. Improving pediatric dosing through pediatric initiatives: what we have learned.
    Rodriguez W; Selen A; Avant D; Chaurasia C; Crescenzi T; Gieser G; Di Giacinto J; Huang SM; Lee P; Mathis L; Murphy D; Murphy S; Roberts R; Sachs HC; Suarez S; Tandon V; Uppoor RS
    Pediatrics; 2008 Mar; 121(3):530-9. PubMed ID: 18310202
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FDA extra-label restriction on drugs.
    Varney JE
    J Am Vet Med Assoc; 1983 Dec; 183(12):1372, 1374-5. PubMed ID: 6654717
    [No Abstract]   [Full Text] [Related]  

  • 43. Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program.
    Cluxton RJ; Li Z; Heaton PC; Weiss SR; Zuckerman IH; Moomaw CJ; Hsu VD; Rodriguez EM
    Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):1-9. PubMed ID: 15546159
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Requirements on content and format of labeling for human prescription drug and biological products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FDA notifications. Revised atazanavir package insert.
    AIDS Alert; 2008 Mar; 23(3):35-6. PubMed ID: 18661642
    [No Abstract]   [Full Text] [Related]  

  • 46. FDA proposes new rules that would require barcoding and new reporting procedures.
    Healthc Leadersh Manag Rep; 2003 Mar; 11(3):12-3. PubMed ID: 12803025
    [No Abstract]   [Full Text] [Related]  

  • 47. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New labeling and patient insert for triazolam approved by FDA.
    Clin Pharm; 1992 Jun; 11(6):467. PubMed ID: 1600683
    [No Abstract]   [Full Text] [Related]  

  • 49. A study of warning letters issued to institutional review boards by the United States Food and Drug Administration.
    Bramstedt KA; Kassimatis K
    Clin Invest Med; 2004 Dec; 27(6):316-23. PubMed ID: 15675112
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Are children getting the right drugs?].
    Bratlid D
    Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3290-2. PubMed ID: 16327857
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A dual track system to give more-rapid access to new drugs: applying a systems mindset to the US food and drug administration (FDA).
    Madden BJ
    Med Hypotheses; 2009 Feb; 72(2):116-20. PubMed ID: 19036524
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FDA puts forth proposal to mandate patient information.
    Wechsler J
    Formulary; 1995 Oct; 30(10):622-3. PubMed ID: 10151725
    [No Abstract]   [Full Text] [Related]  

  • 53. FDA notifications. Updates made to Reyataz package insert.
    AIDS Alert; 2008 Oct; 23(10):116-7. PubMed ID: 18935687
    [No Abstract]   [Full Text] [Related]  

  • 54. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing.
    Breslow LH
    Harvard J Legis; 2003; 40(1):133-93. PubMed ID: 16594116
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A study of warning letters issued to clinical investigators by the United States Food and Drug Administration.
    Bramstedt KA
    Clin Invest Med; 2004 Jun; 27(3):129-34. PubMed ID: 15305804
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Labeling requirements for systemic antibacterial drug products intended for human use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Feb; 68(25):6062-81. PubMed ID: 12577966
    [TBL] [Abstract][Full Text] [Related]  

  • 59. American Academy of Pediatrics. Committee on drugs. Drug testing in children: FDA regulations.
    Pediatrics; 1969 Mar; 43(3):463-5. PubMed ID: 5818481
    [No Abstract]   [Full Text] [Related]  

  • 60. FDA notifications. Raltegravir indication extended for treatment-naive patients.
    AIDS Alert; 2009 Aug; 24(8):93. PubMed ID: 19705587
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.